Navigation Links
CryoLife Announces Implants of First FDA-Cleared SynerGraft(R) Processed Human Cardiac Patch Material
Date:8/18/2009

seased, damaged, malformed or malfunctioning native or prosthetic pulmonary valves. The Company's BioGlue((R)) Surgical Adhesive is FDA approved as an adjunct to sutures and staples for use in adult patients in open surgical repair of large vessels. BioGlue is also CE marked in the European Community and approved in Canada and Australia for use in soft tissue repair. The Company's BioFoam((R)) Surgical Matrix is CE marked in the European Community for use as an adjunct in the sealing of abdominal parenchymal tissues (liver and spleen) when cessation of bleeding by ligature or other conventional methods is ineffective or impractical. BIOGLUE Aesthetic(TM) Medical Adhesive is CE marked in the European Community for periosteal fixation following endoscopic browplasty (brow lift) in reconstructive plastic surgery and is distributed by a third party for this indication. CryoLife distributes HemoStase((TM)), a hemostatic agent, in much of the U.S. for use in cardiac and vascular surgery and in the European Community and Canada for cardiac, vascular, and general surgery, subject to certain exclusions.

Statements made in this press release that look forward in time or that express management's beliefs, expectations or hopes are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include those regarding anticipated effectiveness, benefits and indications for use of CryoPatch SG. These future events may not occur as and when expected, if at all, and, together with the Company's business, are subject to various risks and uncertainties. These risks and uncertainties include that CryoPatch SG may not perform as well as expected or provide all of the benefits anticipated, that the CryoPatch SG has a one year shelf life, and other risk factors detailed in CryoLife's Securities and Exchange Commission filings, including CryoLife's Form 10-K filing for
'/>"/>

SOURCE CryoLife, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. CryoLife Receives FDA 510(k) Clearance for SynerGraft(R) Processed Human Cardiac Patch Material
2. CryoLife Reports Record First Quarter Revenues of $26.7 Million
3. CryoLife Announces Release Date and Teleconference Call Details for 2009 First Quarter Financial Results
4. CryoLife to Present at Sidotis 13th Annual New York Emerging Growth Institutional Forum
5. CryoLife Reports Record Annual Revenues of $105.1 Million for FY 2008
6. CryoLife Announces Release Date and Teleconference Call Details for 2008 Fourth Quarter and Year End Financial Results
7. CryoLife, Inc. Receives Tissue From 100,000th Donor, Marking Industry Milestone
8. CryoLife to Present at 20th Annual Piper Jaffray Health Care Conference
9. CryoLifes Fully Diluted Earnings Per Share Increased 71 Percent to $0.12 in Third quarter of 2008 from $0.07 in Third quarter of 2007
10. CryoLife Announces Release Date and Teleconference Call Details for Third Quarter 2008 Financial Results
11. CryoLife Hosts Worldwide Surgical Congress for the Ross Procedure
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... (PRWEB) August 20, 2014 Not long ... E&L studies should be performed late in the development ... known. But current regulatory trends suggest that, like many ... the rise. In recent years, multiple drug sponsors have ... or address specific questions during phase I/II. It’s not ...
(Date:8/20/2014)... WriteResult®, a leading provider of Electronic Patient ... its myPROpad™ ePRO tablet with the addition of a ... most widely used and well-respected Patient Reported Outcome (PRO) ... is used during clinical trials and in other health ... used to demonstrate Health-Related Quality of Life outcomes (HRQoL) ...
(Date:8/19/2014)... 19, 2014 Shimadzu Scientific Instruments ... Prominence-i and Nexera-i, adding to the company’s extensive ... functionality, an intuitive operating environment, and full automation, ... efficient workflow for conventional to ultra-high-speed analysis. ... and intelligent design so users can begin building ...
(Date:8/19/2014)... Calif. (PRWEB) August 19, 2014 ... campaign to raise $200,000 to fund a corporate ... device. , This development is a critical ... model of care to the implementation of personalized ... method of practicing medicine. , Indiegogo contributions will ...
Breaking Biology Technology:Are Extractable and Leachables going Phase-Appropriate? New Webinar Hosted by Xtalks 2EQ-5D™ Assessment Now Available for iPad 2Shimadzu’s New i-Series Integrated Liquid Chromatography Systems Provide Laboratories Wider Range of Analytical Capabilities 2Shimadzu’s New i-Series Integrated Liquid Chromatography Systems Provide Laboratories Wider Range of Analytical Capabilities 3Cellgen Diagnostics Launches Indiegogo Crowdfunding Campaign for DNA Medical Testing Device 2Cellgen Diagnostics Launches Indiegogo Crowdfunding Campaign for DNA Medical Testing Device 3
... 2011 Vaccinex, Inc. announced today that it has ... 1 clinical trial to assess the safety, tolerability, pharmacokinetics ... patients with advanced solid tumors. (Logo: ... antibody that blocks the activity of semaphorin 4D (SEMA4D). ...
... 4, 2011 Zeus, Inc., a global leader in ... expanded its capabilities and is now able to process ... Class 7 manufacturing environment. This expansion allows for the ... environment, resulting in compliance with stricter regulatory standards. ...
... announces that a new market research report is ... Opportunities in Biosimilar and Biobetter Drugs Markets ... Executive SummaryThe biosimilar and biobetter drugs market has ... following a series of changes in regulatory framework ...
Cached Biology Technology:Vaccinex, Inc. Initiates Clinical Trial of Novel Therapeutic Antibody in Cancer Patients With Advanced Solid Tumors 2Zeus Expands Class 7 Capabilities to Include the Processing of Advanced Polymers 2Reportlinker Adds Emerging Opportunities in Biosimilar and Biobetter Drugs Markets 2
(Date:8/20/2014)... suffered concussions ready to return to action? A new ... athletes who head back on the field with medical ... their abilities to simultaneously walk and do simple mental ... their balance and/or altered walking speed, was found in ... returned to activity in less than a month. Seven ...
(Date:8/20/2014)... pepper causes a burning spiciness that is irresistible to ... pepper,s effect are using their findings to develop a ... can be caused by inflammation or other problems. They ... tested in clinical trials, in ACS, Journal of ... that decades ago, scientists had pegged a compound called ...
(Date:8/20/2014)... could one day be made out of cocoa, rice ... reporting. The novel process they developed and their results, ... and plastic waste problems, appear in the ACS journal ... and colleagues at the Italian Institute of Technology point ... its production reached 288 million tons worldwide, but its ...
Breaking Biology News(10 mins):Recovery reversal seen in Oregon study of returning concussed athletes 2Recovery reversal seen in Oregon study of returning concussed athletes 3
... Calif. The largest genome-wide association study ever ... cat allergies, has identified 16 new genetic associations ... collaboration between 23andMe, the leading personal genetics company, ... Children (ALSPAC), examined data for more than 53,000 ...
... the Denver Police Crime Lab and the University of Colorado, have ... leukocyte (white blood cell) and a cancer cell fuse to form ... ONE , may answer the question of how cancer cells travel ... tissues of the body the deadly process of metastasis. ...
... and medical students each received a one-year, $40,000 ... psoriatic arthritis. The National Psoriasis Foundation Amgen Medical ... scientists studying and treating psoriatic diseases by encouraging ... and psoriatic arthritis as physician researchers. The ...
Cached Biology News:23andMe and ALSPAC identify 16 new genetic associations for pollen, dust-mite and cat allergies 223andMe and ALSPAC identify 16 new genetic associations for pollen, dust-mite and cat allergies 3National Psoriasis Foundation awards 12 psoriasis and psoriatic arthritis research fellowships 2National Psoriasis Foundation awards 12 psoriasis and psoriatic arthritis research fellowships 3
... N,N- bis- (3-D-Gluconamidopropyl)deoxycholamide White solid. ... and CHAPSO. Has reduced electrostatic interactions that ... on DEAE-cellulose. Aggregation number: 8-16. Purity: ... 2 O. Aggregation number 8 - 16, ...
... White crystalline solid. HYGROSCOPIC. Water-soluble zwitterionic detergent ... 252005) but differing in the length of ... extraction of mycoplasma membrane antigens under mild ... TLC. Soluble in H 2 O. ...
Anti-Protein Kinase-A (PKA) Regulatory subunit IIB; rabbit host...
Identify and characterize Phosphoinositide (PI(3,4,5)P3) binding...
Biology Products: